Use of antibody drug conjugate

TW202631204AActive Publication Date: 2026-08-01DAIICHI SANKYO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Filing Date
2014-12-25
Publication Date
2026-08-01

Smart Images

  • Figure TWG2TA001071402_001
    Figure TWG2TA001071402_001
  • Figure TWG2TA001071402_002
    Figure TWG2TA001071402_002
  • Figure TWG2TA001071402_003
    Figure TWG2TA001071402_003
Patent Text Reader

Abstract

The invention provides an antitumor drug with excellent antitumor efficacy and safety profile, exhibiting superior therapeutic effects. An anti-TROP2 antibody is provided, comprising: CDRH1 composed of an amino acid sequence of sequence identification number 23, CDRH2 composed of an amino acid sequence of sequence identification number 24, and CDRH3 composed of an amino acid sequence of sequence identification number 25 in the variable region of its heavy chain; and CDRL1 composed of an amino acid sequence of sequence identification number 26, CDRL2 composed of an amino acid sequence of sequence identification number 27, and CDRL3 composed of an amino acid sequence of sequence identification number 28 in the variable region of its light chain.
Need to check novelty before this filing date? Find Prior Art